Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00186-3/fulltext?dgcid=hubspot_update_feature_updatealerts_lanres&utm_campaign=update-lanres&utm_medium=email&_hsenc=p2ANqtz-892uH4leo1sCuYgKyOCkGXLd5HJHnphC2bSEJvEp5ZGKyuH5AQ5qJh9oH4tqFRnP_e6l3Zb9-cGjqDh3IFTvcWZwTdFw&_hsmi=338784243&utm_content=338419591&utm_source=hs_email